About Us
Sequenom is committed to providing the best genomic and genetic analysis solutions for the research and molecular diagnostic markets.
Sequenom, Inc.
Sequenom, Inc. (NASDAQ: SQNM) designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders.
Technologies employed include mass spectrometry and second generation DNA sequencing. The company's proprietary MassARRAY® system is a high-performance mass spectrometry based DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations. The system delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.
The company was founded in 1994 and employs over 350 employees worldwide. Sequenom is headquartered in San Diego, CA.
Sequenom is committed to improving healthcare through revolutionary genetic analysis solutions.
Sequenom Center for Molecular Medicine, LLC
The Sequenom Center for Molecular Medicine (Sequenom CMM) - a wholly-owned subsidiary, is a molecular diagnostics clinical laboratory located in Grand Rapids, MI and was originally founded as a joint venture between Spectrum Health and the Van Andel Institute. In 2008, Sequenom acquired the laboratory which then became known as Sequenom CMM. The laboratory has a Certificate of Accreditation as a "high complexity" laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is accredited by the College of American Pathologists (CAP). Sequenom CMM's mission is to develop and offer laboratory developed tests as services to physicians, branded under the name SensiGene®.